Calyxt Announces $15 Million Registered Direct Offering
16 Ottobre 2020 - 2:25PM
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced
today that its majority-owned subsidiary Calyxt, Inc. (NASDAQ:
CLXT), a plant-based technology company, has entered into
definitive agreements with institutional investors for the purchase
and sale of 3,750,000 shares of Calyxt’s common stock, at a
purchase price of $4.00 per share, in a registered direct offering.
Cellectis subscribed to purchase 1,250,000 shares in the offering.
Following the registered direct offering, Cellectis will own
approximately 64.7% of Calyxt’s outstanding shares of common stock.
The closing of the offering is expected to occur
on or about October 20, 2020, subject to the satisfaction of
customary closing conditions.
H.C. Wainwright & Co. is acting as the
exclusive placement agent for the transaction.
The gross proceeds to Calyxt from this offering
are expected to be $15 million, before deducting the placement
agent's fees and other offering expenses payable by Calyxt. Calyxt
intends to use the net proceeds from this offering for general
corporate purposes, including to advance its current product
development pipeline, to continue to advance its TALEN® technology
and its intellectual property portfolio, and to support the
execution of its streamlined business model.
The shares of Calyxt’s common stock are being
offered by Calyxt pursuant to a "shelf" registration statement on
Form S-3 (File No. 333-233231) previously filed with the Securities
and Exchange Commission (the "SEC") and declared effective by the
SEC on September 27, 2019. The offering is being made only by means
of a prospectus, including a prospectus supplement, forming a part
of the effective registration statement. A final prospectus
supplement and accompanying prospectus relating to the shares of
common stock being offered will be filed with the SEC. Electronic
copies of the final prospectus supplement and accompanying
prospectus may be obtained on the SEC's website at
http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC
at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at
(646) 975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy Calyxt’s securities,
nor shall there be any sale of such securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About CellectisCellectis is
developing the first of its kind allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients. As a clinical-stage biopharmaceutical company with
over 20 years of expertise in gene editing, Cellectis is developing
life-changing product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation system
to harness the power of the immune system in order to target and
eradicate cancer cells.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing life-saving UCART
product candidates to address unmet needs for multiple cancers
including acute myeloid leukemia (AML), B-cell acute lymphoblastic
leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France,
with additional locations in New York, New York and Raleigh, North
Carolina. Cellectis is listed on the Nasdaq Global Market (ticker:
CLLS) and on Euronext Growth (ticker: ALCLS). For more information,
visit www.cellectis.com.
Follow Cellectis on social media: @cellectis,
LinkedIn and YouTube.
TALEN® is a registered trademark owned by
Cellectis.
For further information, please
contact:
Media contacts:
Jennifer Moore, SVP, Public Relations,
917-580-1088, media@cellectis.comCaitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
IR contact:
Simon Harnest, VP of Corporate Strategy and
Finance, 646-385-9008,simon.harnest@cellectis.com
Disclaimer
This press release contains “forward-looking”
statements that are based on our management’s current expectations
and assumptions and on information currently available to
management. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Further information on
the risk factors that may affect company business and financial
performance is included in Cellectis’ Annual Report on Form 20-F
and the financial report (including the management report) for the
year ended December 31, 2019 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except
as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
PDF available
at: http://ml.globenewswire.com/Resource/Download/3a051db1-cfd2-47aa-8dda-666e43d2cc3d
Grafico Azioni Cellectis Nom Eo 05 (EU:ALCLS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Cellectis Nom Eo 05 (EU:ALCLS)
Storico
Da Apr 2023 a Apr 2024